C. Orndal et al., CYTOGENETIC EVOLUTION IN PRIMARY TUMORS, LOCAL RECURRENCES, AND PULMONARY METASTASES OF 2 SOFT-TISSUE SARCOMAS, Clinical & experimental metastasis, 11(5), 1993, pp. 401-408
The karyotypic pattern at different stages of tumor development may pr
ovide information on tumor progression but few data are available rega
rding human solid tumors. Cytogenetic analysis was performed on the pr
imary tumor and four lung metastases of a synovial sarcoma, and the pr
imary tumor, two consecutive local recurrences, and six pulmonary meta
stases, obtained at two different occasions, of a malignant fibrous hi
stiocytoma (MFH). Simultaneous existence of more than one cytogenetica
lly aberrant clone was also assessed through analysis of more than one
sample from the same surgical specimen. Clonal chromosome aberrations
were detected in all samples from the synovial sarcoma, and in both l
ocal recurrences and five of the metastases from the MFH. All clones i
n both tumors were cytogenetically related. The primary synovial sarco
ma tumor contained two clones, one of which was also found in the lung
metastases, together with a third clone that had acquired additional
aberrations. Four clones with a near-tetraploid chromosome number and
complex aberrations were identified in the MFH. Likely evolutionary pa
thways could be deduced in both cases. In the patient with synovial sa
rcoma one of the pulmonary metastases, rather than the primary tumor,
might well have been the source of another of the pulmonary metastases
. In the MFH the cytogenetic findings indicated the presence of two co
-existing lineages in the primary tumor, one giving rise to the local
recurrences and one to the pulmonary metastases. Our findings show tha
t cytogenetic analysis can be used to establish the chronologic relati
onships between different clones in primary tumors, local recurrences
and distant metastases, to determine what genetic changes are of impor
tance for the metastatic capability of tumor cells, and to help establ
ish the origin of the metastatic lesions.